Nurix Therapeutics (NRIX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NRIX Nurix Therapeutics

Watchlist

22.130
+0.080+0.36%

Trading Nov 25 15:40 ET

1.57BMarket Cap-7631P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 25 07:00 ET
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
MT NewswiresNov 21 09:13 ET
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
MT NewswiresNov 20 17:45 ET
Nurix Therapeutics Receives PRIME Designation From the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
GlobeNewswireNov 20 16:00 ET
Express News | Nurix Therapeutics Receives Prime Designation From the European Medicines Agency for Nx-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
ReutersNov 20 16:00 ET
Express News | Nurix Therapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence 2024
ReutersNov 17 10:30 ET

Comments

Stock_Drift

Nov 17 09:45

$Nurix Therapeutics (NRIX.US)$

Bigmoney Dreamer

Oct 26 10:59

$Nurix Therapeutics (NRIX.US)$
NRIX exhibits a moderately high risk level primarily due to its financial underperformance, demonstrated by substantial net losses and negative free cash flow, indicating financial instability. Additionally, its PE ratio is negative, reflecting market uncertainties regarding future profitability. Despite positive news catalysts, the absence of profitability and the high volatility in the biotechnology sector compounds the riskiness of the stock. Recent positive anal...